EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas
Hematopoietic Stem Cell Transplant is the standard treatment of refractory / recurrent lymphomas, most of conditioning regimens in this cases are BCNU-based as for BEAM & CBV , this agent (BCNU) is well-known for its severe lung toxicity . In our department we tried to assess effectivity and s...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2014-08-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/1791 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846098229169487872 |
|---|---|
| author | Mohamed BEKADJA Tamim ALSULIMAN Rachid BOUHASS Abdessamed ARABI Mohamed BRAHIMI Soufi OSMANI Nabil YAFOUR Souad TALHI |
| author_facet | Mohamed BEKADJA Tamim ALSULIMAN Rachid BOUHASS Abdessamed ARABI Mohamed BRAHIMI Soufi OSMANI Nabil YAFOUR Souad TALHI |
| author_sort | Mohamed BEKADJA |
| collection | DOAJ |
| description | Hematopoietic Stem Cell Transplant is the standard treatment of refractory / recurrent lymphomas, most of conditioning regimens in this cases are BCNU-based as for BEAM & CBV , this agent (BCNU) is well-known for its severe lung toxicity . In our department we tried to assess effectivity and safety of approaches that contain BCNU-free conditioning regimen as for this EAM protocol in Autologous Stem Cell Transplant.
Seventeen patients (ten males, seven females) of either refractory/relapsed or high risk lymphomas received the EAM conditioning regimen in our department from 2011 to 2012 as follows: intravenous Etoposide 200 mg/m2 on days -5,-4,-3 and -2 (total dose of 800 mg\m2); intravenous Ara-C 1000 mg/m2 twice daily on days -5,-4,-3 and -2 (total dose of 8000 mg\m2); and intravenous Melphalan 140 mg/m2 once daily on day -1.
The median follow-up of our patients group was 24 months, (range: 2–31).
ASCT results after EAM conditioning regimen were as follows:
Fifteen patients (88%) achieved complete remission, one patient (6%) had progressive disease post-ASCT, and one more (6%) died within the first 100 days that followed transplantation.
Overall survival at 31 months was 82% while median disease-free survival (DFS) at 27 months were 78% and the median 100-days treatment related morbidity (TRM) was 6%.
Our preliminary study results suggest that EAM regimen as applied in this work had resulted in remarkably good short-term results regarding transplantation-related mortality, overall and disease-free survival. |
| format | Article |
| id | doaj-art-e4fc7046d22040eda2af870e8ddaf40d |
| institution | Kabale University |
| issn | 2035-3006 |
| language | English |
| publishDate | 2014-08-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-e4fc7046d22040eda2af870e8ddaf40d2025-01-02T01:39:06ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062014-08-011EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomasMohamed BEKADJA0Tamim ALSULIMAN1Rachid BOUHASS2Abdessamed ARABI3Mohamed BRAHIMI4Soufi OSMANI5Nabil YAFOUR6Souad TALHI7chief of Hematology and Cell Therapy Department , EHU-Oranhematologist and oncologist in department of hematology and cell therapy EHU-Oranhematologist in department of hematology and cell therapy EHU-Oranhematologist in department of hematology and cell therapy EHU-Oranhematologist in department of hematology and cell therapy EHU-Oranhematologist in department of hematology and cell therapy EHU-Oranhematologist in department of hematology and cell therapy EHU-Oranhematologist in department of hematology and cell therapy EHU-OranHematopoietic Stem Cell Transplant is the standard treatment of refractory / recurrent lymphomas, most of conditioning regimens in this cases are BCNU-based as for BEAM & CBV , this agent (BCNU) is well-known for its severe lung toxicity . In our department we tried to assess effectivity and safety of approaches that contain BCNU-free conditioning regimen as for this EAM protocol in Autologous Stem Cell Transplant. Seventeen patients (ten males, seven females) of either refractory/relapsed or high risk lymphomas received the EAM conditioning regimen in our department from 2011 to 2012 as follows: intravenous Etoposide 200 mg/m2 on days -5,-4,-3 and -2 (total dose of 800 mg\m2); intravenous Ara-C 1000 mg/m2 twice daily on days -5,-4,-3 and -2 (total dose of 8000 mg\m2); and intravenous Melphalan 140 mg/m2 once daily on day -1. The median follow-up of our patients group was 24 months, (range: 2–31). ASCT results after EAM conditioning regimen were as follows: Fifteen patients (88%) achieved complete remission, one patient (6%) had progressive disease post-ASCT, and one more (6%) died within the first 100 days that followed transplantation. Overall survival at 31 months was 82% while median disease-free survival (DFS) at 27 months were 78% and the median 100-days treatment related morbidity (TRM) was 6%. Our preliminary study results suggest that EAM regimen as applied in this work had resulted in remarkably good short-term results regarding transplantation-related mortality, overall and disease-free survival.https://mjhid.org/index.php/mjhid/article/view/1791autologousconditioninglymphomas |
| spellingShingle | Mohamed BEKADJA Tamim ALSULIMAN Rachid BOUHASS Abdessamed ARABI Mohamed BRAHIMI Soufi OSMANI Nabil YAFOUR Souad TALHI EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas Mediterranean Journal of Hematology and Infectious Diseases autologous conditioning lymphomas |
| title | EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas |
| title_full | EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas |
| title_fullStr | EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas |
| title_full_unstemmed | EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas |
| title_short | EAM conditioning regimen followed by autologous hematopoietic Stem Cell Transplantation for relapsed, refractory and high risk lymphomas |
| title_sort | eam conditioning regimen followed by autologous hematopoietic stem cell transplantation for relapsed refractory and high risk lymphomas |
| topic | autologous conditioning lymphomas |
| url | https://mjhid.org/index.php/mjhid/article/view/1791 |
| work_keys_str_mv | AT mohamedbekadja eamconditioningregimenfollowedbyautologoushematopoieticstemcelltransplantationforrelapsedrefractoryandhighrisklymphomas AT tamimalsuliman eamconditioningregimenfollowedbyautologoushematopoieticstemcelltransplantationforrelapsedrefractoryandhighrisklymphomas AT rachidbouhass eamconditioningregimenfollowedbyautologoushematopoieticstemcelltransplantationforrelapsedrefractoryandhighrisklymphomas AT abdessamedarabi eamconditioningregimenfollowedbyautologoushematopoieticstemcelltransplantationforrelapsedrefractoryandhighrisklymphomas AT mohamedbrahimi eamconditioningregimenfollowedbyautologoushematopoieticstemcelltransplantationforrelapsedrefractoryandhighrisklymphomas AT soufiosmani eamconditioningregimenfollowedbyautologoushematopoieticstemcelltransplantationforrelapsedrefractoryandhighrisklymphomas AT nabilyafour eamconditioningregimenfollowedbyautologoushematopoieticstemcelltransplantationforrelapsedrefractoryandhighrisklymphomas AT souadtalhi eamconditioningregimenfollowedbyautologoushematopoieticstemcelltransplantationforrelapsedrefractoryandhighrisklymphomas |